Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer March 12, 2024
FDA Clearance obtained for a First in Human Clinical Study for Stage III/IV Ovarian Cancer Treatment with Autologous Vaccine Therapy, Innocell™ March 12, 2024
Patients Enrolling in Ph 1/2 Clinical Trial of IMNN-001 + Avastin in Advanced Ovarian Cancer March 4, 2024
FDA Grants Priority Review to Supplemental BLA for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma February 26, 2024
Tisotumab Vedotin MAA Validated by EMA for Treatment of Recurrent or Metastatic Cervical Cancer February 26, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
TIVDAK® Supplemental BLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer January 17, 2024
FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer January 17, 2024
23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded January 10, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
Rinatabart Sesutecan FDA Fast Track Designation for Patients with Advanced Ovarian Cancer January 10, 2024
Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial January 4, 2024
FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer January 4, 2024
Confirmatory Ph 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer initiated December 19, 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio December 11, 2023
FDA Grants Priority Review of Supplemental BLA for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer December 11, 2023
